Genetics and Heart Health After Cancer Therapy
Completed
- Conditions
- Breast CancerHereditary Breast/Ovarian Cancer (brca1, Brca2)Heart DiseasesDrug-Induced Cardiomyopathy
- Registration Number
- NCT03510689
- Lead Sponsor
- Abramson Cancer Center at Penn Medicine
- Brief Summary
The overall objective of this study is to use patient-centered in vitro and in vivo models to answer the fundamental question of whether or not pathogenic mutations in BRCA1/2 result in an increased risk of CV disease
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 79
Inclusion Criteria
Not provided
Exclusion Criteria
Not provided
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Left Ventricular Ejection Fraction 6 years
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular pathways link BRCA1/2 mutations to cardiovascular disease risk in cancer survivors?
How does BRCA1/2 mutation status influence cardiovascular outcomes compared to standard-of-care therapies in breast cancer patients?
What biomarkers predict cardiovascular risk in BRCA1/2 carriers post-cancer treatment?
What are the management strategies for anthracycline-induced cardiomyopathy in BRCA1/2 mutation carriers?
How do PARP inhibitors and BRCA1/2 mutations interact to affect heart health in cancer patients?
Trial Locations
- Locations (1)
Abramson Cancer Center of the University of Pennsylvania
🇺🇸Philadelphia, Pennsylvania, United States
Abramson Cancer Center of the University of Pennsylvania🇺🇸Philadelphia, Pennsylvania, United States